TY - JOUR
T1 - Tumour immune escape via P2X7 receptor signalling
AU - Sainz, Ricardo M.
AU - Rodriguez-Quintero, Jorge Humberto
AU - Maldifassi, Maria Constanza
AU - Stiles, Brendon M.
AU - Wennerberg, Erik
N1 - Publisher Copyright:
Copyright © 2023 Sainz, Rodriguez-Quintero, Maldifassi, Stiles and Wennerberg.
PY - 2023
Y1 - 2023
N2 - While P2X7 receptor expression on tumour cells has been characterized as a promotor of cancer growth and metastasis, its expression by the host immune system is central for orchestration of both innate and adaptive immune responses against cancer. The role of P2X7R in anti-tumour immunity is complex and preclinical studies have described opposing roles of the P2X7R in regulating immune responses against tumours. Therefore, few P2X7R modulators have reached clinical testing in cancer patients. Here, we review the prognostic value of P2X7R in cancer, how P2X7R have been targeted to date in tumour models, and we discuss four aspects of how tumours skew immune responses to promote immune escape via the P2X7R; non-pore functional P2X7Rs, mono-ADP-ribosyltransferases, ectonucleotidases, and immunoregulatory cells. Lastly, we discuss alternative approaches to offset tumour immune escape via P2X7R to enhance immunotherapeutic strategies in cancer patients.
AB - While P2X7 receptor expression on tumour cells has been characterized as a promotor of cancer growth and metastasis, its expression by the host immune system is central for orchestration of both innate and adaptive immune responses against cancer. The role of P2X7R in anti-tumour immunity is complex and preclinical studies have described opposing roles of the P2X7R in regulating immune responses against tumours. Therefore, few P2X7R modulators have reached clinical testing in cancer patients. Here, we review the prognostic value of P2X7R in cancer, how P2X7R have been targeted to date in tumour models, and we discuss four aspects of how tumours skew immune responses to promote immune escape via the P2X7R; non-pore functional P2X7Rs, mono-ADP-ribosyltransferases, ectonucleotidases, and immunoregulatory cells. Lastly, we discuss alternative approaches to offset tumour immune escape via P2X7R to enhance immunotherapeutic strategies in cancer patients.
KW - ART1
KW - CD38
KW - CD39
KW - P2X7 receptor
KW - cancer immunotherapy
KW - tumour immune escape
KW - tumour microenvironment
UR - http://www.scopus.com/inward/record.url?scp=85176446055&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176446055&partnerID=8YFLogxK
U2 - 10.3389/fimmu.2023.1287310
DO - 10.3389/fimmu.2023.1287310
M3 - Short survey
C2 - 38022596
AN - SCOPUS:85176446055
SN - 1664-3224
VL - 14
JO - Frontiers in immunology
JF - Frontiers in immunology
M1 - 1287310
ER -